November 2020, Drugs Monitor

(29 Nov 2020) Hydroxychloroquine- Zinc supplements did not enhance the clinical efficacy of HCQ

November 30, 2020

Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial https://doi.org/10.1007/s12011-020-02512-1 This was a randomized clinical trial (NCT04447534) conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection… Continue reading "(29 Nov 2020) Hydroxychloroquine- Zinc supplements did not enhance the clinical efficacy of HCQ"

(26 Nov 2020) Favipiravir- associated with significant clinical and laboratory improvements

November 27, 2020

Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey https://doi.org/10.3906/sag-2008-33 This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. Forty patients who completed a full course (at least… Continue reading "(26 Nov 2020) Favipiravir- associated with significant clinical and laboratory improvements"

(25 Nov 2020) ACE-I/ARB therapy – mortality is not associated with ACE-I/ARB therapy

November 27, 2020

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study https://doi.org/10.1177/1074248420976279 This multi-center, prospective study ( NCT4357535) enrolled patients hospitalized for COVID-19 and receiving one or more antihypertensive agents to manage either hypertension… Continue reading "(25 Nov 2020) ACE-I/ARB therapy – mortality is not associated with ACE-I/ARB therapy"

(25 Nov 2020) Hydroxychloroquine- combination with AZT helpful in recovery

November 27, 2020

Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial https://doi.org/10.1111/ijcp.13856 The study included 161 patients who were admitted with positive RT-PCR and clinical symptoms of COVID-19. In terms of severity, 53 (32.9%) patients had mild condition,… Continue reading "(25 Nov 2020) Hydroxychloroquine- combination with AZT helpful in recovery"

(23 Nov 2020) Interferons – PEG Interferon lambda 1a did not shorten the duration of viral shedding

November 27, 2020

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial https://www.medrxiv.org/content/10.1101/2020.11.18.20234161v1 In a randomized placebo-controlled trial (NCT04331899 )in 120 patients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a… Continue reading "(23 Nov 2020) Interferons – PEG Interferon lambda 1a did not shorten the duration of viral shedding"

(22 Nov 2020) Remdesivir, Dexamethasone- combination helps reduce mortality

November 27, 2020

Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19 https://www.medrxiv.org/content/10.1101/2020.11.19.20234153v1 In a multicenter, retrospective cohort study, 342 received remdesivir and 157 received remdesivir plus dexamethasone. Remdesivir recipients on room air or nasal cannula oxygen had a faster… Continue reading "(22 Nov 2020) Remdesivir, Dexamethasone- combination helps reduce mortality"

(22 Nov 2020) Anakinra, Methylprednisolone- Combination beneficial for hyperinflammation and respiratory failure

November 27, 2020

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study https://doi.org/10.1016/j.jaci.2020.11.006 120 COVID-19 patients with hyperinflammation (median age 62 years, 80.0% males, median PaO2:FiO2 ratio 151, 32.5% on mechanical ventilation) were evaluated. Of these,… Continue reading "(22 Nov 2020) Anakinra, Methylprednisolone- Combination beneficial for hyperinflammation and respiratory failure"

(21 Nov 2020) Anakinra- found to be efficient for severe COVID-19 pneumonia and high oxygen requirement

November 27, 2020

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study https://doi.org/10.1016/j.ijid.2020.11.149 A prospective, open-label, interventional study (ISRCTN74727214) in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received… Continue reading "(21 Nov 2020) Anakinra- found to be efficient for severe COVID-19 pneumonia and high oxygen requirement"

(20 Nov 2020) Tocilizumab- low dose associated with rapid improvement in clinical and laboratory measures

November 27, 2020

COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia https://doi.org/10.1002/CPT.2117 A single-arm phase 2 trial (NCT04331795) of low-dose tocilizumab in non-intubated hospitalized adult patients with COVID-19, radiographic pulmonary infiltrate, fever, and C-reactive protein… Continue reading "(20 Nov 2020) Tocilizumab- low dose associated with rapid improvement in clinical and laboratory measures"

(20 Nov 2020) Favipiravir- significant improvement in time to clinical cure

November 27, 2020

Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial https://doi.org/10.1016/j.ijid.2020.11.142 In this randomized, open-label, parallel-arm, multicenter, Phase 3 trial (CTRI/2020/05/025114), adults (18-75 years) with RT-PCR-confirmed COVID-19… Continue reading "(20 Nov 2020) Favipiravir- significant improvement in time to clinical cure"

Month: November 2020